Ari Melnick
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Ari Melnick | |
|---|---|
Ari Melnick is an Argentine-born physician and biomedical researcher specialising in haematological malignancies and cancer epigenetics.[1][2] Since 2025, he is the Director of the Josep Carreras Leukaemia Research Institute in Spain.[3]
Education
[edit]Melnick studied medicine at the University of Buenos Aires, graduating in 1990. He subsequently continued his professional and academic career in the United States.[4][5]
Career
[edit]Melnick has held positions at the Mount Sinai School of Medicine in New York and later joined Weill Cornell Medicine. At Weill Cornell he directs the Haematologic Malignancies Research Program, a role he has combined since 2013 with his appointment as Gebroe Family Professor of Haematology/Oncology. In 2025 he was appointed Director of the Josep Carreras Leukaemia Research Institute.[4]
Research
[edit]Melnick is an international reference in the fields of blood cancers and cancer epigenetics.[6][7] He played a leading role[8] in one of the first large-scale epigenomic studies in humans.[9] Through this and subsequent research, Melnick and collaborators demonstrated that aberrant epigenetic programming is a hallmark of cancer[10] and that epigenetic diversity contributes significantly[11] to tumour fitness and unfavorable patient outcomes.[2][1][3]
His therapeutic approaches have been approved by the United States Food and Drug Administration or advanced to phase III clinical trials.[2][1]
Awards and honours
[edit]In recognition of his contributions to translational research in haematology, Melnick received the Ernest Beutler Prize in Translational Research from the American Society of Hematology.[3][12]
Melnick is a member of the Board of Directors of the Leukemia and Lymphoma Society and the Lymphoma Research Foundation.[3]
References
[edit]- 1 2 3 "Ari Melnick". Melnick Lab. Retrieved 2025-11-01.
- 1 2 3 "A new chapter in leukaemia and hematologic disease research". healthcare-in-europe.com. Retrieved 2025-11-01.
- 1 2 3 4 "Ari Melnick sustituye a Manel Esteller como director del Instituto de Investigación Josep Carreras". La Vanguardia (in Spanish). 2025-04-22. Retrieved 2025-11-01.
- 1 2 "Director". www.carrerasresearch.org. Retrieved 2025-11-05.
- ↑ "Playing the Long Game in Lymphoma Research". Lymphoma Research Foundation. Retrieved 2025-11-07.
- ↑ "Melnick, Ari M." vivo.weill.cornell.edu. Retrieved 2025-11-07.
- ↑ "Ari Melnick". Melnick Lab. Retrieved 2025-11-07.
- ↑ "ORCID". orcid.org. Retrieved 2025-11-07.
- ↑ Chambwe, Nyasha; Kormaksson, Matthias; Geng, Huimin; De, Subhajyoti; Michor, Franziska; Johnson, Nathalie A.; Morin, Ryan D.; Scott, David W.; Godley, Lucy A.; Gascoyne, Randy D.; Melnick, Ari; Campagne, Fabien; Shaknovich, Rita (2014-03-13). "Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes". Blood. 123 (11): 1699–1708. doi:10.1182/blood-2013-07-509885. ISSN 1528-0020. PMC 3954051. PMID 24385541.
- ↑ Duy, Cihangir; Béguelin, Wendy; Melnick, Ari (2020-12-01). "Epigenetic Mechanisms in Leukemias and Lymphomas". Cold Spring Harbor Perspectives in Medicine. 10 (12) a034959. doi:10.1101/cshperspect.a034959. ISSN 2157-1422. PMC 7706582. PMID 32014848.
- ↑ Teater, Matt; Dominguez, Pilar M.; Redmond, David; Chen, Zhengming; Ennishi, Daisuke; Scott, David W.; Cimmino, Luisa; Ghione, Paola; Chaudhuri, Jayanta; Gascoyne, Randy D.; Aifantis, Iannis; Inghirami, Giorgio; Elemento, Olivier; Melnick, Ari; Shaknovich, Rita (2018-01-15). "AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis". Nature Communications. 9 (1): 222. Bibcode:2018NatCo...9..222T. doi:10.1038/s41467-017-02595-w. ISSN 2041-1723. PMC 5768781. PMID 29335468.
- ↑ "2020 Ernest Beutler Lecture and Prize Presented to Ari Melnick, MD, and Courtney DiNardo, MD". The ASCO Post. December 10, 2020. Retrieved 2025-11-07.